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ABSTRACT
Objective: The objective of this study was to examine
the association between diabetes, and both urinary
bladder cancer (UBC) risk and mortality.
Methods: We conducted a retrospective cohort study
using data from the UK Clinical Practice Research
Datalink (CPRD) linked to the Office of National
Statistics (ONS). Patients diagnosed with diabetes
mellitus type 1 or 2, or using antidiabetic drugs
(ADDs), were compared to matched non-diabetic
controls. Cox proportional hazards models were used
to estimate the risk and mortality of UBC. We adjusted
for age, sex, smoking status and body mass index.
Results: The cohort included 329 168 patients using
ADD, and 307 315 controls with 1295 and 1071
patients, respectively, diagnosed as having UBC during
follow-up. The adjusted HRs of UBC were 0.77 (95%
CI 0.57 to 1.05) and 1.04 (95% CI 0.96 to 1.14) for
type 1 and 2 diabetes, respectively. These results were
similar if we restricted our analysis to an inception
cohort. We noticed a small increased risk during the
first year after diagnosis (HR=1.26 (95% CI 1.05 to
1.52)), which could be explained by detection bias.
There was no influence of the severity of diabetes as
measured by the glycated haemoglobin. Mortality of
UBC was not increased for patients with either type 1
(HR=0.95 (95% CI 0.39 to 2.34)) or type 2 diabetes
(HR=1.16 (95% CI 0.91 to 1.46)).
Conclusions: Neither the risk of UBC nor the
mortality from UBC was increased in patients with type
1 and patients with type 2 diabetes in the CPRD data.
BACKGROUND
The global 2013 estimate of diabetes mellitus
prevalence among adults (aged 20–79 years)
was 8.3%, affecting 382 million adults in the
world and 6.6% in the UK.1 Between 2010
and 2030, the number of adults with diabetes
in developing countries is expected to
increase by 69%, and by 20% in developed
countries.2 3 In 2012, more than 400 000
cases of urinary bladder cancer (UBC)
occurred worldwide, making it the seventh
most common type of cancer.4 It is more fre-
quent in men than in women, and age is
now widely accepted as the greatest single
risk factor for developing UBC. Cigarette
smoking and specific occupational expo-
sures, such as carcinogenic dyes for painters
and some genetic polymorphisms, are the
other main known causes of UBC.5 Previous
meta-analyses from cohort and case–control
studies have shown an increased risk of UBC
associated with type 2 diabetes with relative
risks (RR) ranging from 1.11 (95% CI 1.00
to 1.23) to 1.32 (95% CI 1.18 to 1.49).6–9
There is also evidence for a positive associ-
ation between type 2 diabetes and mortality
from UBC (RR=1.33 (95% CI 1.14 to 1.55).7
However, misclassification of type 1 and 2
diabetes was not excluded in these studies,
because diagnostic codes were lacking and
details about the diabetic history (duration,
metabolic control) were not considered.
Two studies on type 1 diabetes reported an
increased overall cancer incidence by 20%,
while the mechanisms remain unclear.10 11
The observed number of bladder cancer
cases in these studies is very small, ranging
from 4 to 27 cases.10–12 The objective of this
study was to examine the association between
diabetes mellitus, and both UBC risk and
mortality, taking into account diabetes
Strengths and limitations of this study
▪ The Clinical Practice Research Datalink (CPRD) is
a large population-based cohort representative of
the total UK population.
▪ Detailed longitudinal information on drug pre-
scription is available within the CPRD, and 95%
and 80% of patients with type 1 and 2 diabetes,
respectively, had received a formal diabetes
diagnosis.
▪ Smoking status was available for all patients in
our analysis.
▪ Detailed information about the cause of death is
available for 44% of the patients by linking the
patients to the Office of National Statistics (ONS)
data.
▪ The effect of different antidiabetic drug medica-
tions is not considered in our analyses and this
is a major limitation.
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duration, metabolic control as expressed by glycated
haemoglobin (HbA1c) and type of diabetes.
METHODS
Data sources
We conducted a retrospective cohort study using data
from the UK Clinical Practice Research Datalink (CPRD)
( January 1987–October 2013) linked to the Office of
National Statistics (ONS) ( January 1998–January 2012).
The CPRD comprises prospectively collected compu-
terised medical records of over 10 million patients under
the care of more than 600 general practitioners (GPs) in
the UK. The Read classification is used to enter medical
diagnoses and procedures, and prescriptions are recorded
based on the UK Prescription Pricing Authority Dictionary.
The recorded information on diagnoses and drug use
was validated, and proved to be of high quality.13 The
ONS provided data for the cause(s) of death and the
exact date of death as recorded on death certificates by
a registered medical practitioner attending to the
patient during their last period.
Study population
All patients with at least one prescription of antidiabetic
drugs (ADDs) (oral antidiabetic drugs (NIADs) and/or
insulin) and aged above 18 years during the period of
valid CPRD data collection were included. Each ADD
user was matched to one control patient by year of
birth, sex and practice. Controls could have any disease
as long as they were non-diabetic patients at baseline
and during follow-up. The date of the first ADD pre-
scription defined the index date and controls were
assigned the same index date as their matched ADD
user. All participants with missing data for smoking
status, a history of any cancer prior to the index date,
except non-melanoma skin cancer, or a diagnosis of ges-
tational diabetes or secondary diabetes ever during
follow-up were excluded. All control patients who used
diabetes treatment or had ever been diagnosed with
type 1 or 2 diabetes ever during follow-up were
excluded. All ADD users with diagnoses of type 1 and 2
diabetes were excluded as well, as were patients aged
30 years and older without a diagnosis of diabetes, who
used insulin only at baseline. All study participants were
followed up from the index date to either the end of
data collection, the date of transfer of the patient out of
the practice area, or the patient’s death.
Exposure
Patients with type 1 diabetes were defined as those
patients with a formal diagnosis of type 1 diabetes (as
recorded in CPRD) or younger than 30 years and using
insulin only at index date. Patients with type 2 diabetes
were all patients with a formal diagnosis of type 2 dia-
betes (as recorded in CPRD) or using an oral ADD at
index date. The total period of follow-up for each
patient (patients with diabetes and unexposed controls)
was divided into fixed time periods of 90 days. Age was
determined at the start of each interval. The classifica-
tion of type 1 and 2 diabetes, as well as sex, smoking
status and body mass index (BMI), was determined at
baseline. Diabetes duration was assessed in a time-
dependent manner by estimating the time since the
date of the first ADD prescription (the index date).
Diabetes control was assessed in a time-dependent
manner using the most recent HbA1c record before the
start of each time interval and within the previous year.
Outcomes
The primary outcome was UBC, as defined by Read codes,
and was assessed in the complete CPRD study population
( January 1987–October 2013). The secondary outcome
was bladder cancer-related mortality as recorded on death
certificates (International Classification of Diseases
(ICD-10) categories C65, C67) and was assessed in the
population eligible for linkage between CPRD and ONS
data (44% of the participants). The period of follow-up
was restricted to the time that ONS data were available
( January 1998–January 2012).
Risk factors
The major covariates of interest included age, sex,
smoking status and BMI. Smoking status was characterised
at baseline as current, former or lifelong non-smoker.
Statistical analysis
Analyses were conducted using Cox proportional
hazards models with various subanalyses. As time scale
we used time since first ADD use. We tested the propor-
tional hazard assumption by comparing patients with
diabetes to non-diabetes controls. The assumption was
not violated. The first analysis compared the risk of UBC
in ADD users with that in control patients to yield an
estimate of the RR (as a HR) of UBC associated with
ADD use. The calculations were adjusted for age, sex,
smoking status and BMI. Results were stratified to type 1
and type 2 diabetes. A sensitivity analysis was performed
excluding women with polycystic ovarian syndrome
(PCOS). In a secondary analysis, risks were estimated for
an inception cohort of ADD users using a 1-year lead-in
time. The risk of UBC for patients with incident type 2
diabetic was further stratified by disease duration, sex
and HbA1c. The risk of UBC mortality in ADD users
compared with that of controls was assessed by Cox
models as well and results were stratified by type of dia-
betes. All data management and statistical analyses were
conducted using SAS V.9.1/9.2 software.
This study was approved by the Medicines and
Healthcare products Authorities’ Independent Scientific
Advisory Committee, protocol number 13_050R.
RESULTS
After exclusion of all patients with a diagnosis of gesta-
tional diabetes (1983 and 154 for ADD users and
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controls, respectively), or secondary diabetes (485 and
70 for ADD users and controls, respectively), or cancer
prior to index date (34 955 and 34 384 for ADD users
and controls, respectively) or missing data for smoking
status during follow-up (13 416 and 27 558 for ADD
users and controls, respectively), the study population
consisted of 329 168 patients with diabetes of whom
30 823 (9.4%) and 298 345 (90.6%) had type 1 and 2
diabetes, respectively, and 307 315 controls. Patients
diagnosed with type 1 and 2 diabetes at baseline (7614)
and patients without diagnosis, using insulin only at
baseline and 30 years or older (10 178), were not
included in our analysis.
Table 1 shows baseline characteristics. The mean age
at index date was 58 years. Forty-six per cent of the
patients with diabetes had a BMI of 30 or above in con-
trast with 30% of the control participants.
During nearly 6 years of follow-up, 1071 patients of
the control group and 1295 of the ADD users were diag-
nosed with bladder cancer. Patients with type 1 diabetes
had no significantly lower risk of UBC (HR=0.77 (95%
CI 0.57 to 1.05)) than patients with type 2 diabetes
(HR=1.04 (95% CI 0.96 to 1.14)) based on a Wald test
(p=0.054). The results for incident ADD users were
similar (table 2).
For patients with incident type 2 diabetes, we noticed an
increased risk of UBC (HR=1.26 (95% CI 1.05 to 1.52))
during the first year after the first ADD prescription, com-
pared to controls, which disappeared in subsequent years
(table 3). Sixty per cent of the bladder cancers developed
during the first 5 years after diabetes onset. There was no
difference in UBC risk between male and female patients
with type 2 diabetes (HR=1.11 (95% CI 0.98 to 1.25) and
1.01 (95% CI 0.79 to 1.29), respectively). In patients with
type 2 diabetes, there was no influence of HbA1c as an
indicator of diabetes severity on UBC risk (table 4).
UBC-related mortality was neither increased in patients
with type 1 diabetes (HR=0.79 (95% CI 0.32 to 1.94)) nor
in patients with type 2 diabetes, compared to controls
(HR=1.05 (95% CI 0.83 to 1.33)) (table 5).
Table 1 Baseline characteristics of antidiabetic drug (ADD) users and non-diabetic controls
ADD users Controls
Characteristics N=329 168 (Per cent) 307 315 (Per cent)
Follow-up time (years; mean) 5.91 5.66
Sex
Female 152 683 (46.4) 148 791 (48.4)
Male 176 485 (53.6) 158 524 (51.6)
Age at index date (years; mean, median) 58.6 (60.0) 58.2 (60.0)
18–29 19 716 (6.0) 19 184 (6.2)
30–39 26 236 (8.0) 28 065 (9.1)
40–49 43 659 (13.3) 41 539 (13.5)
50–59 68 564 (20.8) 62 400 (20.3)
60–69 80 562 (24.5) 71 975 (23.4)
70–79 62 064 (18.9) 56 632 (18.4)
80+ 28 367 (8.6) 27 520 (9.0)
Smoking status
Never smoker 168 832 (51.3) 166 190 (54.1)
Current smoker 66 903 (20.3) 70 765 (23.0)
Former smoker 93 433 (28.4) 70 360 (22.9)
Body mass index (kg/m2)
<20.0 6 587 (2.0) 16 769 (5.5)
20.0–24.9 54 212 (16.5) 96 636 (31.4)
25.0–29.9 105 547 (32.1) 103 315 (33.6)
≥30.0 150 152 (45.6) 55 827 (18.2)
Unknown 12 670 (3.8) 34 768 (11.3)
ADD users
Formal diabetes diagnosis
Type 1 28 964 (8.8)
Type 2 239 021 (72.6)
No diabetes diagnosis
Insulin only at index date and <30 years 1859 (0.6)
Others 59 324 (18.0)
Patients with diabetes
Type 1 diabetes* 30 823 (9.4)
Type 2 diabetes† 298 345 (90.6)
*Defined as either formal diagnosis of type 1 diabetes or insulin only at index date and younger than 30 years.
†Defined as either formal diagnosis of type 2 diabetes or ADD use at index date.
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DISCUSSION
We could not detect a significantly increased risk of
UBC nor of increased mortality due to UBC in patients
with type 1 and 2 diabetes compared to controls even if
we reduced our cohort to incident ADD users. However,
we noticed an increased risk of UBC in patients with
type 2 diabetes during the first year after diagnosis.
Diabetes control, as expressed by HbA1c, had no influ-
ence on the UBC risk in patients with type 2 diabetes.
Previous meta-analyses reported an increased risk.6–9
Even when these meta-analyses6–8 were restricted to
studies that adjusted for smoking, there was still an
increased RR ranging from 1.32 (95% CI 1.18 to 1.49)
to 1.48 (95% CI 1.25 to 1.77), comparable to our RR for
type 2 diabetes. On the other hand, in several studies,
diabetes ascertainment was based on self-reporting.8
Those studies had an RR of 1.34 (95% CI 1.11 to 1.62).
The increased risk of UBC in patients with diabetes
decreased and significance disappeared when diabetes
was asserted by other methods (RR=1.11 (95% CI 0.95
to 1.31)). Furthermore, not all studies distinguished
between diabetes type 1 and 2. Most of the studies
excluded type 1 diabetes as a diagnosis of diabetes
before 30 years of age.7 8 Subgroup analysis of studies
restricted to Europe did not show an increased risk of
UBC in patients with type 2 diabetes.6–8 Hence, our
results are in line with those of European studies.12 14–21
It is not clear why there is a difference between
European studies and those of other regions.
We did not find an increased risk of bladder cancer in
diabetes type 1, which is in line with the results found in
Sweden10 11 and in the UK.12
An increased risk of UBC during the first year after
diabetes diagnosis was found in several other
Table 2 Risk of bladder cancer in antidiabetic drug (ADD) users compared with controls, by type of diabetes and in incident
ADD users
ADD users (N=329 168) versus controls
(N=307 315)
Incident ADD users (N=179 598) versus
controls (N=233 505)
Exposure category
Bladder
cancer
N (%)
Age-sex adj
HR (95% CI)
Fully adj HR*
(95% CI)
Bladder
cancer
N (%)
Age-sex adj
HR (95% CI)
Fully adj HR*
(95% CI)
Controls 1071 (0.3) 1 1 732 (0.3) 1 1
ADD users 1295 (0.4) 1.09 (1.00 to 1.18) 1.03 (0.95 to 1.12) 746 (0.4) 1.15 (1.04 to 1.27) 1.08 (0.97 to 1.20)
Type 1 diabetes† 44 (0.0) 0.76 (0.56 to 1.02)§ 0.77 (0.57 to 1.05) 5 (0.0) 0.65 (0.27 to 1.58) 0.65 (0.27 to 1.57)
Type 2 diabetes‡ 1251 (0.4) 1.10 (1.02 to 1.20) 1.04 (0.96 to 1.14) 741 (0.4) 1.15 (1.04 to 1.28) 1.09 (0.97 to 1.21)
*Incident=all index patients are included after 1 year lead-in time without antidiabetic drug (ADD) prescription; fully adjusted for age, sex,
smoking and body mass index.
†Defined as either formal diagnosis of type 1 diabetes or insulin only at index date and younger than 30 years.
‡Defined as either formal diagnosis of type 2 diabetes or ADD use at index date.
§Significant difference between type 1 diabetes mellitus and type 2 diabetes mellitus, based on Wald test.
Table 3 Risk of bladder cancer in incident patients with type 2 diabetes mellitus compared with controls, by duration of
disease and sex
Type 2 diabetes (N=175 083) versus controls (N=233 505)
Exposure category
Bladder cancer
N (%)
Age-sex adj HR
(95% CI)
Fully adj HR*
(95% CI)
Controls 732 (0.3) 1 1
Type 2 diabetes 741 (0.4) 1.15 (1.04 to 1.28) 1.09 (0.97 to 1.21)
Duration of disease (years)†
<1 149 (0.1) 1.34 (1.12 to 1.61) 1.26 (1.05 to 1.52)
1–<2 95 (0.1) 1.17 (0.95 to 1.45) 1.10 (0.88 to 1.37)
2–<5 201 (0.1) 1.02 (0.87 to 1.19) 0.95 (0.81 to 1.12)
5–<10 224 (0.1) 1.22 (1.05 to 1.41) 1.14 (0.98 to 1.33)
10–<15 67 (0.0) 1.19 (0.93 to 1.54) 1.14 (0.88 to 1.47)
≥15 5 (0.0) 0.43 (0.18 to 1.04) 0.42 (0.18 to 1.02)
Sex
Male‡ 604 (0.3) 1.19 (1.06 to 1.33) 1.11 (0.98 to 1.25)
Female§ 137 (0.1) 1.03 (0.82 to 1.29) 1.01 (0.79 to 1.29)
*Incident=all index patients are included after 1 year lead-in time without antidiabetic drug (ADD) prescription; fully adjusted for age, sex,
smoking and body mass index.
†As measured from first prescription.
‡Male patients with type 2 diabetes versus male controls.
§Female patients with type 2 diabetes versus female controls.
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studies.20 22–24 Likewise, for colorectal, lung, breast, liver,
cervical, endometrial, ovarian, pancreatic and prostate
cancers, a significantly increased risk was found within
the months following diabetes onset.10 25 26 This most
likely indicates the presence of a detection bias, in the
sense that the diagnosis of diabetes leads to increased
medical attention, and thus to earlier detection of any
present but undiagnosed cancer. This phenomenon has
also been observed immediately after the diagnosis of
prostate cancer. The incidence of UBC was 18 times
higher in patients with prostate cancer due to diagnostic
bias.27 28 On the other hand, in contrast with some
other studies, we could not confirm the hypothesis that
fewer physician visits in the year before diabetes diagno-
sis increases the risk of bladder cancer diagnosis in con-
trast with some other studies.24 26 Apart from the
increased risk of UBC during the first year of diabetes
diagnosis, possibly due to detection bias, we did not find
an association between diabetes duration and develop-
ing bladder cancer. Seeing that nearly 50% of the
patients had a follow-up of more than 5 years and only
40% of the bladder cancers were diagnosed after these
5 years, while only 10% was diagnosed after 10 years, we
can conclude that having diabetes for more than 5 years
did not alter the risk of UBC.
Our finding of no association between HbA1c and
cancer risk is consistent with the results of a recent
meta-analysis of major randomised controlled trials.29
The strength of this study was that the CPRD is a large
population-based cohort, representative of the total UK
population. Type 2 diabetes accounts for 85% to 95% of
all diabetes in high-income countries.1 In the UK, 10% of
the people with diabetes have type 1,30 which was con-
firmed in our analysis (9.4%). We had detailed longitu-
dinal information on drug prescription, and 95% and
80% of the patients with type 1 and 2 diabetes, respect-
ively, had received a formal diabetes diagnosis. Patients
with type 1 and 2 diabetes at baseline, and patients
without diagnosis, using insulin only at baseline and
30 years or older, were excluded from our analysis.
Consulting rates for diabetes in the CPRD have been
compared with equivalent data from the fourth National
Morbidity Survey in General Practice, confirming the val-
idity of the morbidity data in the CPRD.31 Furthermore,
since 2004, GPs have been stimulated to provide ‘quality
care’ by the Quality and Outcomes Framework (QOF).
The UK has a National Service Framework for Diabetes
(NSF).32 Guidelines to be followed by the GPs are out-
lined in the guideline for type 133 and 2 diabetes34 of the
National Institute of Health and Care Excellence
(NICE). For diagnosis, the NICE guideline refers to the
International Diabetes Federation (IDF) Diabetes Atlas.1
Diagnosis of diabetes is directly linked with prescription
of ADD whereas Impaired Glucose Tolerance (IGT) is
referred to as people whose blood glucose levels are high
but not as high as those in people with diabetes. Our
Table 4 Risk of urinary bladder cancer in patients with type 2 diabetes mellitus by HbA1c level at most recent measurement
Patients with type 2 diabetes (N=298 345)
Exposure category
Bladder cancer
N (%)
Age-sex adj HR
(95% CI)
Fully adjusted HR*
(95% CI)
Type 2 diabetes 1251 (0.4)
HbA1C level†
HbA1c <6% 57 (0.0) 1 1
6≤HbA1c <7.0% 278 (0.1) 1.18 (0.89–1.57) 1.19 (0.90–1.58)
7≤HbA1c <8.0% 248 (0.1) 1.16 (0.87–1.55) 1.18 (0.89–1.58)
8≤HbA1c <9.0% 110 (0.0) 1.09 (0.79–1.50) 1.10 (0.80–1.52)
HbA1c ≥9.0% 106 (0.0) 1.17 (0.85–1.62) 1.17 (0.85–1.62)
Missing 452 (0.2) 0.91 (0.68–1.20) 0.92 (0.69–1.21)
*Fully adjusted for age, sex, smoking and body mass index.
†6%=42 mmol/mol, 7%=53 mmol/mol, 8%=64 mmol/mol, 9%=75 mmol/mol.
HbA1c, glycated haemoglobin.
Table 5 Risk of urinary bladder cancer (UBC) mortality in antidiabetic drug (ADD) users compared with controls, by type of
diabetes mellitus
ADD user (N=143 566) versus controls (N=114 994)
Exposure category
Bladder cancer
mortality N (%)
Age-sex adjusted
HR (95% CI)
Fully adjusted
HR* (95% CI)
Controls 145 (0.1) 1 1
ADD users 179 (0.1) 1.04 (0.83 to 1.29) 1.04 (0.83 to 1.31)
Type 1 diabetes 5 (0.0) 0.73 (0.30 to 1.79) 0.79 (0.32 to 1.94)
Type 2 diabetes 174 (0.1) 1.05 (0.84 to 1.31) 1.05 (0.83 to 1.33)
*Fully adjusted for age, sex, smoking and body mass index.
Goossens ME, et al. BMJ Open 2015;5:e007470. doi:10.1136/bmjopen-2014-007470 5
Open Access
group.bmj.com on June 2, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
cohort was restricted to those patients receiving ADD.
Furthermore, we had HbA1c values for 1251 of the 1295
patients with bladder cancer. So, 96% of the patients have
additional proof of being diabetic.
Metformin can also be used to treat obesity or PCOS.
We have no means to test the possible effect of metfor-
min prescribed for obesity, although the clinical impres-
sion exists that such treatments tend to be relatively
short. In our cohort, 12 841 women were diagnosed with
PCOS. None of them developed UBC. A sensitivity ana-
lysis, excluding those PCOS women, showed exactly the
same HRs. Additionally, we have information on the
smoking status of all patients who were included in our
analysis, which is essential given that smoking is one of
the major risk factors for bladder cancer.5 The link with
the ONS data allowed us to have detailed information
about the cause of death for 44% of patients.
The fact that the effect of different antidiabetic drug
medications was not considered in our analyses is a
major limitation. We are aware of the fact that metfor-
min can have a protective effect on cancer3 35 and that
pioglitazone could be associated with an increased risk
of bladder cancer.36–40 This was, however, beyond the
scope of this study.
With this study, and against the background of all pre-
vious research, the likelihood of a clinically relevant asso-
ciation between diabetes and UBC risk has become very
limited. The influence of antidiabetic treatment on
bladder cancer risk, however, is still contradictable and
requires further study in the future.
CONCLUSION
Neither the risk of UBC nor the mortality from UBC was
observed to be increased in patients with type 1 or type
2 diabetes in the CPRD data. Our results are in line with
those of previous European studies.
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